1,25-Dihydroxy-16-Ene-Vitamin D3.
Research-backed vitamin with potential health benefits. It's a modified form of Vitamin D designed to regulate cell growth with less impact on blood calcium levels. It's purely a research tool for now.
Reviewed March 2026
- Category
- Vitamin
What 1,25-Dihydroxy-16-Ene-Vitamin D3 is, and what it does.
- Does it work
- This one suits researchers working on vitamin D receptor biology. Anyone after everyday vitamin D support is looking at ordinary D3, which carries the human data.
- How much to take
- Don't. There is no established dose for human supplementation. Any amount is pure guesswork.
- Time to feel it
- Nobody has measured a timeline in people. Receptor-level changes turn up on blood calcium and gene expression readouts rather than in how a day feels.
- The first dose
- Nothing. This isn't for acute effects. It's a molecule for long-term study.
- With regular use
- Completely unknown for general use. That's the entire point. The data doesn't exist.
- How well tolerated
- The safety profile is not established for the public. It was designed to be less calcemic than active D, but 'less' isn't 'zero' and other risks are unknown.
- How it feels
- You won't feel a thing. This compound works at a cellular level over long periods. It is not for mood, energy, or any perceptible effect.
- The overlooked benefit
- The 16,17 double bond changes how fast 24-hydroxylase clears it, so it lingers differently from the natural hormone. That half-life shift is the point of the design.
1,000 to 4,000 IU a day is where 1,25-Dihydroxy-16-Ene-Vitamin D3 works.
Source: Holick 2017 meta-analysis + Endocrine Society
The proof, claim by claim.
These words describe the research, not the molecule's worth. Research strength is how much work stands behind one claim, and it is never a product score.
1,25-Dihydroxy-16-Ene-Vitamin D3 is documented in the library; the clinical read is in the queue. Nothing about the strength of the research prints until the read is done.
- Vitamin D receptor activationIn vitro study
- Intestinal calcium absorption signallingAnimal study
- Cell differentiation signallingIn vitro study
- Metabolic half-life of side-chain modified analoguesAnimal study
Questions people ask about 1,25-Dihydroxy-16-Ene-Vitamin D3.
- Is this better than regular Vitamin D3?
- No. It's different, not better. It's designed for a specific research purpose (cell regulation) and lacks the extensive safety and efficacy data of Vitamin D3.
- Can I take this for my bones?
- No. It's intentionally designed to have less effect on calcium metabolism, which is the primary mechanism for bone health. Use standard Vitamin D3 for that.
- Is it safe to take?
- No. Its safety for general consumption is unknown. It's a research chemical, not a dietary supplement.
- Where can I buy it?
- You shouldn't. It's sold by chemical supply companies for laboratory use, not for human consumption.
- What are the side effects?
- Unknown in the long term for humans taking it as a supplement. That's why it should be avoided.
Why these belong in the same formula. Each row says what the basis is, from settled biochemistry through to a trial that measured the pair.
Active vitamin D metabolites bind the vitamin D receptor and drive transcription of the intestinal calcium transport machinery, including the apical channel and the calcium-binding protein that ferries calcium across the enterocyte. Without an active metabolite present, transcellular calcium absorption falls back on passive paracellular movement. A 16-ene analogue is built on that same receptor-binding scaffold, so calcium handling is the pathway it sits closest to.
The same receptor pathway that raises intestinal calcium uptake also raises expression of the sodium-dependent phosphate cotransporter in the small intestine. Calcium and phosphate handling therefore move together under active vitamin D. This is textbook mineral physiology rather than a claim specific to any analogue.
The cytochrome P450 hydroxylases that convert cholecalciferol to 25-hydroxyvitamin D and then to the 1,25-dihydroxy form are magnesium-dependent, as is the binding protein that carries the metabolites. An already-dihydroxylated analogue bypasses those activation steps, so the magnesium dependence applies upstream rather than to the analogue itself. That distinction is worth stating rather than assuming the usual pairing carries over.
Active vitamin D increases transcription of osteocalcin, and vitamin K is the cofactor for the carboxylase that converts osteocalcin's glutamate residues to the calcium-binding gamma-carboxyglutamate form. One raises the supply of the protein, the other makes it able to bind mineral. The pairing is a genuine sequential dependency in normal bone mineral handling.
The vitamin D receptor works as a heterodimer with the retinoid X receptor, which retinoic acid receptors also require. High retinoid exposure can compete for the shared RXR pool and shift transcription away from vitamin D response elements. This is a well-described nuclear receptor interaction and it applies to any VDR ligand, including a synthetic analogue.
Boron has been reported to slow the catabolic clearance of several steroid and secosteroid metabolites, which would extend their circulating time. The mechanism is not fully mapped and the human data are limited. It is listed as a modulating interaction rather than a dependable one.
Cholecalciferol becomes active only after two hydroxylation steps, the second of which is tightly regulated by parathyroid hormone, calcium and the feedback enzyme 24-hydroxylase. An already-active analogue bypasses that control and also induces the same catabolic enzyme, so combining the two stacks receptor occupancy while suppressing native activation. Any product containing both is a compounding situation, not an additive one.
Carbonate is a high-elemental-calcium salt that needs gastric acid for dissolution. When intestinal calcium transport is already upregulated by an active vitamin D metabolite, the absorbed fraction of a given calcium load rises. The combination raises total calcium delivered and is a reason for monitoring rather than a benefit to assume.
Calcium and sodium are reabsorbed in overlapping regions of the renal tubule, and a high sodium load increases urinary calcium loss. That works against the direction active vitamin D pushes mineral balance. The interaction sits at the kidney rather than at the receptor.
Vitamin D and its analogues are lipophilic secosteroids whose oral absorption depends on incorporation into mixed micelles. A medium-chain triglyceride vehicle keeps the molecule in solution and is the standard carrier in oil-based softgels. The vehicle governs delivery, not potency.
Nothing specific on file for 1,25-Dihydroxy-16-Ene-Vitamin D3. Match the label to the daily amount above, and tell your doctor what you take.
Not medical advice. Show the label to your pharmacist.What 1,25-Dihydroxy-16-Ene-Vitamin D3 actually does.
These molecules work by switching on genes: they dock into a receptor inside the cell nucleus that then binds DNA.
Ordinary vitamin D has to be changed twice by the liver and kidney before it works. This one already carries both changes.
Changing the tail of the molecule changes how tightly it is carried in the blood and how fast the body breaks it down.
The active form switches on the enzyme that destroys it, which is the body's own brake.
Where 1,25-Dihydroxy-16-Ene-Vitamin D3 comes from.
This is made by chemists, not extracted from anything. A steroid molecule is taken apart and rebuilt in stages to add the exact chemical changes wanted, then purified carefully because the wrong isomer behaves differently.
Chemically synthesised. The molecule is identical to the one a plant or an animal makes, and building it deliberately means a known purity, a fixed dose and no crop contaminants. For several nutrients this is the only route that reaches a usable amount.
Vitamin D analogue chemistry starts from steroid nucleus material of plant or animal origin, most often ergosterol or a cholesterol-derived intermediate, chosen because the four-ring core is already assembled.
The B ring of the steroid nucleus is opened to give the characteristic 9,10-secosteroid framework of the vitamin D family, the step that separates a sterol from a vitamin D.
The 16,17 double bond and the 25-hydroxyl are introduced by directed chemistry on the CD ring and side chain, which is what distinguishes the analogue from the natural hormone.
The A ring fragment carrying the 1-alpha and 3-beta hydroxyls is coupled to the modified CD ring fragment, a convergent strategy used across this compound class because it avoids installing the triene late.
Secosteroid syntheses generate geometric and stereoisomers that differ in receptor binding, so preparative chromatography and recrystallisation carry the purity burden.
Structure is confirmed by nuclear magnetic resonance and mass spectrometry, and content is set by chromatographic assay against a reference standard, because the active amounts are at the microgram scale.
The purified analogue is dissolved into an oil vehicle or complexed onto a carrier before it can be dosed, since neat microgram quantities cannot be blended uniformly.
Specific synthetic routes for vitamin D analogues are typically covered by patents or held as trade secrets, so the exact reagents, protecting groups and step order behind any commercial lot are usually not published.
The forms it comes in.
FDA Disclaimer: These statements have not been evaluated by the Food and Drug Administration. This information is for educational purposes only and is not intended to diagnose, treat, cure, or prevent any disease. Consult your healthcare provider before starting any supplement regimen.